.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Chinese Patent Office
Federal Trade Commission
Johnson and Johnson
Cantor Fitzgerald
Argus Health
US Army
Julphar
Healthtrust
Colorcon

Generated: June 25, 2017

DrugPatentWatch Database Preview

RAPIVAB Drug Profile

« Back to Dashboard

Which patents cover Rapivab, and what generic Rapivab alternatives are available?

Rapivab is a drug marketed by Biocryst and is included in one NDA. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-seven countries.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the peramivir profile page.

Summary for Tradename: RAPIVAB

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list42
Clinical Trials: see list2
Patent Applications: see list39
Drug Prices:see details
DailyMed Link:RAPIVAB at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biocryst
RAPIVAB
peramivir
SOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes6,503,745► SubscribeY ► Subscribe
Biocryst
RAPIVAB
peramivir
SOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes► Subscribe► Subscribe
Biocryst
RAPIVAB
peramivir
SOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes6,562,861► SubscribeY ► Subscribe
Biocryst
RAPIVAB
peramivir
SOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes8,778,997► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: RAPIVAB

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2007117241► Subscribe
Japan2013256527► Subscribe
South Korea20160129105► Subscribe
European Patent Office1040094► Subscribe
Germany69840674► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Novartis
McKesson
Express Scripts
Baxter
McKinsey
Fuji
Deloitte
Dow
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot